SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 765 shares, a decrease of 88.5% from the August 31st total of 6,640 shares. Based on an average daily volume of 43,794 shares, the short-interest ratio is currently 0.0 days.
SAB Biotherapeutics Price Performance
SABSW traded down $0.00 during trading on Friday, reaching $0.01. The stock had a trading volume of 3,544 shares, compared to its average volume of 73,112. The stock’s 50 day moving average is $0.02 and its two-hundred day moving average is $0.02. SAB Biotherapeutics has a one year low of $0.00 and a one year high of $0.20.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
See Also
- Five stocks we like better than SAB Biotherapeutics
- 3 Defense Stocks Riding Nuclear, Missile, and Aerospace Demand
- SoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement
- These 3 Overlooked Stocks Have Big Money Behind Them
- Darden Restaurants Serves Up Fresh Catalysts for a Stock Price Rally
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
